Full Breakdown
FDA Approval of Orca-Bio’s Tregzi Cell Therapy to Cut Chronic GVHD in Blood Cancer Transplants
7/2/2026, 11:00:42 AM
FDA Approval of Orca-Bio’s Tregzi Cell Therapy
The FDA approved Orca Bio’s Tregzi (Orca-T) on June 30 2026, an allogeneic regulatory T-cell therapy that uses hematopoietic stem and progenitor cells (HSPCs) for matched-donor hematopoietic stem cell transplantation in adults with acute myeloid leukemia, acute lymphoblastic leukemia or myelodysplastic syndromes. Approval follows the Phase 3 Precision-T trial.
Background & Context
Allogeneic HSCT can cure blood cancers but often triggers graft-versus-host disease (GVHD). Conventional grafts contain only ~1 % Tregs. Orca’s platform isolates Tregs and combines them with stem cells to suppress GVHD. Stemming from Stanford research, it was commercialized after Orca’s 2016 spin-out.
Key Figures & Groups
Key participants: Orca CEO Nate Fernhoff; FDA CBER Acting Director Karim Mikhail; Stanford’s Robert Negrin; Dana-Farber’s Robert J. Soiffer; Memorial Sloan Kettering’s Dr. Miguel-Angel Perales.
Data & Statistics
- Chronic GVHD-free survival at 12 months: 78 % (Tregzi) vs 38.4 % (control); cumulative incidence of moderate-to-severe chronic GVHD: 12.6 % vs 44 %.
- Overall survival: 94 % (Tregzi) vs 83 % (control), not statistically significant (P = 0.12).
- Non-relapse mortality: 3.4 % vs 13.2 %.
- Common >=20 % adverse events: mucositis, diarrhea, rash, viral infections.
Why It Matters
Reduced chronic GVHD improves patient quality of life, lowers long-term immunosuppression costs and may cut healthcare spending for blood-cancer survivors. The precision-manufacturing model could extend to autoimmune diseases and broader markets.
Official Statements & Responses
FDA Acting Director Karim Mikhail called the therapy a genuine new approach to reconstitute immunity. Orca CEO Nate Fernhoff called the approval a defining moment for the company. Stanford’s Robert Negrin called it a defining moment for the transplant community.
Criticism & Opposition
Robert J. Soiffer warned that cyclophosphamide (PTCy) now dominates GVHD prophylaxis and that Orca-T’s performance against PTCy remains untested, urging follow-up.
Conflicting Reports & Gaps
Sources report overall survival as 94 % versus 83 % and also as 93.9 % versus 83.1 %, reflecting rounding differences. The survival advantage did not reach statistical significance (P = 0.12). Follow-up beyond one year and direct comparison with PTCy regimens are absent.
Verbatim Quotes
- “Today’s approval marks a defining moment for Orca Bio and for the future of allogeneic transplant, which has long offered curative potential, but also carries significant risks like graft versus host disease,” — Nate Fernhoff, CEO, Orca Bio
- “Today’s approval offers a genuine new approach that can help reconstitute the immune system while substantially reducing that risk and reflects the promise of what cellular therapy can deliver for patients.” — Karim Mikhail, Acting Director, FDA CBER
- “a defining moment for the transplant community.” — Robert Negrin, Professor of Medicine, Stanford Medicine
- “Despite less pharmacological GVHD prophylaxis, Orca-T improved survival free from chronic GVHD due to less GVHD and fewer deaths,” — Investigators, Precision-T trial
What’s Next
Orca will test Tregzi with reduced-intensity conditioning, advance the Orca-Q program to further sculpt donor cells, and expand production at a Princeton facility. The firm secured $250 million in financing and set a wholesale price of $428,000 per dose.
